Daniel Hall7 hours 57 minutes ago
For more than a decade, GLP-1 treatment for weight loss has required a weekly injection with a pre-filled pen that needed to be stored in the fridge. This acted as a barrier to entry for many potential patients who may be needle-averse or would struggle to stick to the strict storage and administration routine
This is beginning to change. The arrival of an oral form of semaglutide is one of the more significant developments in obesity treatment in recent years because it removes those barriers and aligns with the way many patients would prefer to take their medication
The Obstacles Injectable GLP-1 Never Quite Solved
Fear of needles is fairly common and it has quietly kept some patients away from GLP-1 treatment altogether. Beyond needle anxiety, injectable semaglutide also comes with practical friction. The pens require refrigeration before first use, which complicates travel and limits storage options for patients without reliable fridge space
A Familiar Ingredient in a New Format
Wegovy oral tabletswere approved by the Medicines and Healthcare products Regulatory Agency (MHRA) on 11 June 2026, becoming the first GLP-1 receptor agonist tablet licensed for weight loss and weight management in the UK. The tablet contains the same active ingredient as the injectable version (semaglutide) though only a small amount of an oral dose is absorbed compared with an injection. To compensate, the tablet uses an absorption enhancer that protects the medication as it passes through the stomach, and treatment follows a gradual step-up schedule, starting at 1.5mg and increasing every 30 days up to a 25mg maintenance dose, over roughly the first three months.
What the Clinical Trials Found
In the Phase 3 OASIS 4 trial, adults taking the 25mg maintenance dose for 64 weeks lost an average of 16.6% of their starting body weight when they adhered fully to treatment, compared with 2.7% among those taking a placebo. When the analysis accounted for participants who discontinued treatment early or added other weight loss interventions, the average fell to a still notable 13.6%, against 2.2% on placebo. Around three-quarters of participants lost at least 5% of their body weight, and close to a third lost 20% or more.
As with the injectable formulation, gastrointestinal side effects, mainly nausea, vomiting and diarrhoea, were reported more frequently than with placebo, and these were generally described as mild to moderate
What Pharmacists Are Hearing From Patients
For pharmacies dispensing weight loss treatment, the appeal of an oral option is already changing the conversations patients have before starting treatment. Ana Carolina Goncalves fromPharmica, a leading UK online pharmacy, said the shift reflects something prescribers have heard from patients for years without always being able to offer an alternative. “An oral option does not remove every barrier to weight loss treatment, but it removes one of the most common ones we hear directly from patients. For people who have put off starting semaglutide purely because of the injection, having a tablet with a comparable evidence base finally gives them a route into treatment that did not exist before.”
Not a Straightforward Substitute
The tablet is not simply a like-for-like swap for the injection. It must be taken first thing in the morning on an empty stomach, with no more than a small amount of plain water, and patients need to wait at least 30 minutes before eating, drinking anything else or taking other oral medicines, since absorption is highly sensitive to timing. The 25mg oral dose and the 2.4mg weekly injection have not been studied head to head, so any comparison between the two remains indirect. Wegovy tablets also remain a prescription-only treatment assessed on an individual basis and are not yet available through the NHS, with any future NHS access depending on separate evaluation.
Why This Reaches Beyond One Medication
The significance of an oral GLP-1 treatment goes beyond convenience for any single patient. Removing the need for refrigeration and self-injection lowers the practical barrier to prescribing and monitoring treatment at scale, which matters for a drug class already reshaping how obesity is treated across primary care and private practice alike. Whether that translates into wider NHS adoption will depend on cost-effectiveness evaluation rather than the format of the medicine alone, but the direction of travel in GLP-1 development suggests injectable treatment may not remain the only serious option for very much longer.
Daniel Hall
Business Expert
Daniel Hall is an experienced digital marketer, author and world traveller. He spends a lot of his free time flipping through books and learning about a plethora of topics.
Daniel Hall is an experienced digital marketer, author and world traveller. He spends a lot of his free time flipping through books and learning about a plethora of topics
View more
Trending
1Jack Khattar: Innovator, Business Leader, and Founder, President and CEO of Supernus Pharmaceuticals
Issac Thomas
2Steve Collis: Pharmaceutical Distribution Leader and Former Chairman, President, and CEO of Cencora
Felix Yim
3Why Hairline Design Matters: The Growing Popularity of Forehead Reduction Surgery in Turkey
Daniel Hall
4How Can Surgery Centers Gain Better Visibility Across the Full Case Lifecycle?
Daniel Hall
5UK Wasted £10bn on Defective PPE That Left NHS Staff Vulnerable, Covid Inquiry Reveals
Felix Yim
